Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(7):506-507; doi:10.1093/jnci/96.7.506
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Benowitz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benowitz, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

Although European Laboratories Welcome Free Use of BRCA2, Access Still in Question

Steven Benowitz

The first 10% of the full text of this article appears below.

While researchers in Europe cheered the February announcement that the charity Cancer Research U.K. would allow publicly owned laboratories to freely use its newly obtained European patent on the cancer susceptibility gene BRCA2, many are uncertain what this will mean in practice.

The picture is muddied by the fact that both Cancer Research U.K. and Myriad Genetics of Salt Lake City own separate patents on the gene. Myriad, in fact, also has patents on BRCA1 in both the United States and Europe. Its patents give the company . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?